DNA Health Testing: What Consumer Genomics Can (and Can't) Tell You

The Consumer Genomics Landscape in 2026

The global consumer genomics market has matured significantly since 23andMe launched in 2006. Today, over 30 million people have taken a consumer DNA test, and the range of health insights offered has expanded dramatically — from ancestry composition to BRCA cancer risk variants, polygenic risk scores for heart disease, pharmacogenomic drug metabolism profiling, and even sleep chronotype genetics.

But these tests are not created equal, and understanding what they measure — and more importantly, what they don't measure — is essential for using them intelligently.

How Consumer DNA Tests Work

Most consumer tests use a technology called genotyping arrays (SNP chips). Your saliva sample provides DNA, which is amplified and then scanned against a microarray that checks specific locations (single nucleotide polymorphisms, or SNPs) across your genome. A typical consumer test looks at 500,000 to 2 million SNP positions out of the ~3 billion base pairs in your genome.

This is different from whole genome sequencing (WGS), which reads your entire genome. WGS provides more complete data but is more expensive and the clinical interpretation is more complex. A few companies (Nebula Genomics, Dante Labs) offer consumer WGS, but the actionable value over genotyping arrays is limited for most health applications today.

What Consumer DNA Tests Can Tell You

1. Polygenic Risk Scores (PRS)

A polygenic risk score aggregates thousands of small genetic variants, each contributing a tiny effect, into a single score that estimates your relative risk for a complex disease (heart disease, type 2 diabetes, breast cancer, etc.). These are probabilistic, not deterministic — they tell you your risk relative to the population, not whether you will develop a disease.

Trait	Heritability	PRS Predictive Power	Actionability
Coronary artery disease	~50%	Good (top 2% have 3–5× risk)	High (statins, lifestyle)
Type 2 diabetes	~40%	Moderate	High (exercise, diet)
Breast cancer (BRCA1/2)	Variable	High for rare variants	High (screening, prophylaxis)
Alzheimer's (APOE ε4)	~60–80%	Moderate (APOE ε4 = 3–12× risk)	Moderate (lifestyle prevention)
Athletic performance traits	Variable	Low-moderate	Low (training informed by other data)

Important limitation: Most PRS models were developed primarily in European ancestry populations. Predictive accuracy is lower in non-European populations due to differences in LD patterns and effect sizes across ancestral groups. This is an active area of research improvement.

2. Monogenic Disease Carriers

Some variants are highly penetrant — having the variant strongly predicts disease. Examples include BRCA1/BRCA2 (breast/ovarian cancer), APOE ε4 (Alzheimer's risk), Factor V Leiden (thrombophilia), and certain cardiovascular channelopathies. Consumer tests can detect these, but FDA-cleared tests with rigorous validation are preferred over non-clinical consumer reports for medical decisions.

3. Pharmacogenomics (PGx)

This is arguably the most immediately actionable area of consumer genomics. Your CYP450 enzyme genes determine how quickly you metabolize many common medications:

• CYP2C19: Metabolizes clopidogrel (Plavix), omeprazole, SSRIs. Poor metabolizers get less benefit from clopidogrel (higher stroke risk). Ultra-rapid metabolizers may need higher SSRI doses.
• CYP2D6: Metabolizes codeine, tamoxifen, many antidepressants. Poor metabolizers don't convert codeine to morphine (no pain relief); ultra-rapid metabolizers can experience toxicity.
• DPYD: Metabolizes 5-fluorouracil (cancer chemotherapy). Poor metabolizers face life-threatening toxicity at standard doses.
• TPMT/NUDT15: Metabolize thiopurine drugs used in IBD and leukemia. Variants dramatically affect safe dosing.

4. Nutrigenomics

Genetic variants can influence nutrient metabolism, absorption, and requirements:

• MTHFR C677T: Affects folate metabolism. Homozygous variants (TT) have reduced MTHFR enzyme activity — relevant for methylated B vitamin supplementation and pregnancy planning.
• VDR variants: Influence vitamin D receptor sensitivity — may explain why some people need higher vitamin D doses to achieve adequate serum levels.
• APOE ε4 + saturated fat: Carriers have larger LDL increases in response to saturated fat intake than non-carriers.
• FTO variants: Associated with appetite regulation and obesity risk, though effect sizes are modest (<1 kg average weight difference per risk allele).

What Consumer DNA Tests Cannot Tell You

• Your destiny: Genetics is probabilistic. Lifestyle, environment, and epigenetics can dramatically modify genetic risk. Having a high PRS for heart disease is a prompt for prevention, not a sentence.
• Most of the variation in complex traits: For traits like intelligence, athletic ability, or even BMI, hundreds of thousands of variants each explain tiny fractions. Current PRS models for these traits predict less than 20% of trait variance — the rest is environment, unmeasured genetics, and gene-environment interactions.
• Variants not on the chip: Rare variants (<1% population frequency) are often missed by genotyping arrays. Whole exome or genome sequencing is needed for comprehensive rare variant detection.
• Epigenetic state: DNA methylation, histone modifications, and other epigenetic marks — which profoundly influence gene expression — are not measured by standard consumer tests. Biological age clock tests (measuring methylation) are a separate product category.

Consumer DNA Testing Platforms Compared

Platform	Focus	Health Reports	Raw Data	Best For
23andMe Health + Ancestry	Health + ancestry	FDA-cleared reports + wellness	Yes (downloadable)	Broadest consumer health suite
AncestryDNA + Health	Ancestry-first, health add-on	Health traits, carrier status	Yes	Ancestry detail + basic health
Genomind Professional PGx	Pharmacogenomics	Mental health drug metabolism	Via provider	Psychiatric medication optimization
SelfDecode	Health optimization	250+ reports, supplement recs	Upload existing raw data	Detailed biohacker reports
Nebula Genomics	Whole genome sequencing	Continually updated	Full WGS data	Future-proofed data depth

How to Use Your DNA Results

1. Download your raw data — always. This is your genetic data forever. Store it securely and use it with multiple analysis platforms.
2. Focus on actionable variants first — MTHFR, APOE status, CYP450 pharmacogenomics, and BRCA/high-penetrance disease variants have the clearest implications.
3. Use PRS as one input among many — combine with bloodwork (lipids, glucose, HbA1c), imaging (CAC scoring, DEXA), and wearable data for a more complete picture.
4. Bring results to a clinician — especially for pharmacogenomics or high-penetrance disease variants. Many results are clinically significant and require medical interpretation.
5. Don't over-interpret trait reports — caffeine metabolism, exercise response, and sleep chronotype reports are based on a handful of variants with small effect sizes. Use them as interesting data points, not definitive guides.

Best DNA Health Testing Products

Privacy Considerations

DNA data is uniquely personal and permanent. Before testing:

• Review the company's data sharing policies — opt out of research sharing if desired
• Law enforcement access: US companies may receive legal orders for genetic data; GnomAD-style opt-outs exist in some platforms
• Store raw data in encrypted local storage, not solely cloud-based
• Consider a separate email account for your genetic testing account to reduce cross-platform data linkage

The Bottom Line

Consumer DNA testing in 2026 offers genuine health value — particularly in pharmacogenomics, high-penetrance disease variant screening, and nutrigenomics. The key is approaching results with calibrated expectations: genetics is powerful but probabilistic, and the most actionable insights sit in a few specific areas rather than the dozens of trait reports on offer. Download your raw data, work with pharmacogenomics and clinically significant variants first, and use PRS scores as one input in a comprehensive health picture rather than an oracle.